ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q3 2025 Earnings Call Transcript

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q3 2025 Earnings Call Transcript November 10, 2025

ARS Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.51768 EPS, expectations were $-0.45.

Operator: Good morning. And welcome to ARS Pharmaceuticals conference call. At this time, all participants are in a listen-only mode. After the company’s prepared remarks, we will open the line for questions. Please be advised that today’s conference is being recorded. I’ll now turn the...